Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cameron West

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Clinica Chimica Acta; International Journal of Clinical Chemistry|April 10, 2012
Therapeutic monitoring of benzodiazepines in the management of pain: current limitations of point of care immunoassays suggest testing by mass spectrometry to assure accuracy and improve patient safetyCharles Mikel, Amadeo J Pesce, Murray Rosenthal, et al.
Frontiers in Oncology|November 21, 2022
GZ17-6.02 kills prostate cancer cells <i>in vitro</i> and <i>in vivo</i>Laurence Booth, Jane L Roberts, Cameron West, et al.
Oncotarget|March 5, 2024
GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cellsLaurence Booth, Jane L Roberts, Cameron West, et al.
Frontiers in Oncology|September 28, 2020
GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor SignalingLaurence Booth, Cameron West, Daniel Von Hoff, et al.
Anti-Cancer Drugs|March 11, 2022
Mechanisms of GZ17-6.02 resistanceLaurence Booth, Cameron West, Daniel Von Hoff, et al.
Frontiers in Oncology|May 3, 2021
Corrigendum: GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells <i>via</i> Autophagy and Death Receptor SignalingLaurence Booth, Cameron West, Daniel Von Hoff, et al.
JAAD Case Reports|July 5, 2021
Cutaneous mucormycosis following COVID-19 vaccination in a patient with bullous pemphigoidKishan M Shah, Cameron West, Jana Simpson, et al.
Frontiers in Oncology|April 26, 2021
GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma CellsLaurence Booth, Cameron West, Daniel Von Hoff, et al.
Journal of Cellular Physiology|January 18, 2020
GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacyLaurence Booth, Jane L Roberts, Cameron West, et al.
Anti-Cancer Drugs|March 11, 2025
GZ17-6.02 interacts with carboplatin and etoposide to kill neuroblastoma cellsMichael R Booth, Laurence Booth, Jane L Roberts, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Clinica Chimica Acta; International Journal of Clinical Chemistry|April 10, 2012
Therapeutic monitoring of benzodiazepines in the management of pain: current limitations of point of care immunoassays suggest testing by mass spectrometry to assure accuracy and improve patient safetyCharles Mikel, Amadeo J Pesce, Murray Rosenthal, et al.
Frontiers in Oncology|November 21, 2022
GZ17-6.02 kills prostate cancer cells <i>in vitro</i> and <i>in vivo</i>Laurence Booth, Jane L Roberts, Cameron West, et al.
Oncotarget|March 5, 2024
GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cellsLaurence Booth, Jane L Roberts, Cameron West, et al.
Frontiers in Oncology|September 28, 2020
GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor SignalingLaurence Booth, Cameron West, Daniel Von Hoff, et al.
Anti-Cancer Drugs|March 11, 2022
Mechanisms of GZ17-6.02 resistanceLaurence Booth, Cameron West, Daniel Von Hoff, et al.
Frontiers in Oncology|May 3, 2021
Corrigendum: GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells <i>via</i> Autophagy and Death Receptor SignalingLaurence Booth, Cameron West, Daniel Von Hoff, et al.
JAAD Case Reports|July 5, 2021
Cutaneous mucormycosis following COVID-19 vaccination in a patient with bullous pemphigoidKishan M Shah, Cameron West, Jana Simpson, et al.
Frontiers in Oncology|April 26, 2021
GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma CellsLaurence Booth, Cameron West, Daniel Von Hoff, et al.
Journal of Cellular Physiology|January 18, 2020
GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacyLaurence Booth, Jane L Roberts, Cameron West, et al.
Anti-Cancer Drugs|March 11, 2025
GZ17-6.02 interacts with carboplatin and etoposide to kill neuroblastoma cellsMichael R Booth, Laurence Booth, Jane L Roberts, et al.
Pageof 5